By Drug Target Review2025-10-03T09:21:07
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2023-02-16T14:53:10
Sponsored by Cell Signaling Technology
2023-01-20T14:24:55
Sponsored by Leica Microsystems
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2023-03-20T13:41:33
Sponsored by Bio-Techne
Site powered by Webvision Cloud